Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jul-Aug;17(4B):2955-8.

Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer

K N Gaarenstroom  1 , J M Bonfrer, C M Korse, G G Kenter, P Kenemans
Affiliations
  • PMID: 9329574

Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer

K N Gaarenstroom et al. Anticancer Res. 1997 Jul-Aug.

Abstract

Background: The value of serum Cyfra 21-1 level was compared with tissue polypeptide antigen (TPA), and squamous cell carcinoma antigen (SCC-Ag) in squamous cell cervical cancer.

Materials and methods: Pre- and post-treatment serum levels of patients were compared with lymph node status, parametrial involvement, and prognostic data.

Results: Pretreatment serum levels of each marker were significantly related to tumor stage, tumor size and the presence of either lymph node metastases or parametrial involvement. The clinical performance of each marker in predicting extracervical disease at initial diagnosis appeared to be similar. None of these tests achieved the conditions of a perfect test. Pretreatment serum levels of each marker showed prognostic value in the univariate analysis. The clinical performance of post-treatment SCC-Ag levels in predicting complete remission versus the presence of tumor during follow-up was better than Cyfra 21-1 or TPA.

Conclusion: SCC-Ag appears to be more useful than Cyfra 21-1 for monitoring patients with cervical cancer.

PubMed Disclaimer